MMS Holdings Inc, a contract research organisation (CRO), announced yesterday that it has named Dr Mike Poole, MD, FACP as the member of board of scientific advisors.
Currently a venture partner at Biomatics Capital Inc, Dr Poole has more than 25 years of experience in the pharmaceutical industry, most recently having led external investments in the Office of the President for Global Health at the Bill and Melinda Gates Foundation. In this advisory role, Dr Poole will offer guidance on the design, conduct, and reporting of global phase two to four clinical trials, the implementation of clinical development plans, and global regulatory filings. He has supported a wide range of indications from analgesia, pain, neurology, Alzheimer's Disease, psychiatry, infectious disease and more. Prior to joining the Gates Foundation, Dr Poole served as vice president and head of Neuroscience Innovation at AstraZeneca, chief medical officer for Link Medicine and Hypnion, and he was vice president of Neuroscience Development at Wyeth and Pfizer.
Dr Uma Sharma, chief scientific officer of MMS Holdings, said, 'In the global regulatory landscape, sponsors demand CRO leaders who can provide the highest levels of guidance and visionary leadership – making Dr Mike Poole the perfect addition to our already strong team of advisors. Mike's impressive body of work and industry influence is a key ingredient, highlighting the way that MMS is redefining the CRO experience for pharmaceutical companies of every size. Additionally, his excellent way of clear concise communication is what I have always admired and am happy to have our clients benefit from.'
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial